This is a Phase 2b randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of three active dose regimens of MORF-057 in adult patients with moderately to severely active Ulcerative Colitis (UC).
1 Primary · 1 Secondary · Reporting Duration: From baseline to 12 weeks
Experimental Treatment
Non-Treatment Group
280 Total Participants · 4 Treatment Groups
Primary Treatment: Group 2 · Has Placebo Group · Phase 2
Age 18 - 85 · All Participants · 6 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Ohio | 100.0% |
18 - 65 | 100.0% |
Clinical Study Site | 100.0% |
Met criteria | 100.0% |